FDA says desmopressin may pose risk of seizure

12/4/2007 | Forbes · Wall Street Journal, The

Patients taking desmopressin, a bed-wetting treatment for children, may be at risk of hyponatremia, a lack of sodium in the blood that can cause seizures and death, the FDA warned Tuesday. The agency urged discontinuing use of desmopressin -- sold under brands such as DDAVP, DDVP and Stimate nasal spray -- in patients with fever and vomiting.

View Full Article in:

Forbes · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA